Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Autopsy study sheds light on how electric fields fight brain cancer

NCT ID NCT03194971

First seen Apr 10, 2026 · Last updated Jun 22, 2026 · Updated 13 times

Summary

This study looked at brain tissue from 20 glioblastoma patients who had been treated with Tumor Treating Fields (TTFields) before they died. Researchers examined the tissue under a microscope to count active and inactive tumor cells. The goal was to understand how TTFields affect cancer cells at the cellular level.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Froedtert & the Medical College of Wisconsin

    Milwaukee, Wisconsin, 53226, United States

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Tumor Treating Fields (TTFields) delivered via Optune device

What this could lead to

If successful, this study could reveal how TTFields work at a cellular level, potentially guiding better use of the therapy for glioblastoma.

What could go wrong

This is a small, observational autopsy study with only 20 patients. It cannot prove that TTFields improve survival or symptoms, and findings may not apply to all patients.

Conditions

The condition(s) this trial relates to.

brain cancer glioblastoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.